RxDoctor Payments Data

Amy Folker

Nurse Practitioner · River Forest, ILNPI 1598827008

Payments from drug & device makers

$2,115in general payments, 2019–2025

Across 23 payments — averaging $91.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • BETA Bionics, Inc.$465
  • Tandem Diabetes Care, Inc.$230
  • Bayer$214
  • Dexcom, Inc.$201
  • Novo Nordisk$169
  • Averitas Pharma Inc.$144
  • plus $691 from 7 others

What the payments were for

  • Food & beverage$2,05297%
  • Education$633%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,115 in reported general payments places this provider in the 90th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$46,058
Medicare patients
260
Services billed
634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide400$486,635
JardianceEmpagliflozin217$261,736
TrulicityDulaglutide184$244,893
MounjaroTirzepatide67$71,625
Tresiba Flextouch U-100Insulin Degludec117$71,552
Fiasp FlextouchInsulin Aspart (Niacinamide)75$63,932
Tresiba Flextouch U-200Insulin Degludec36$54,578
RybelsusSemaglutide40$52,875
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/745$49,922
Humalog Kwikpen U-200Insulin Lispro31$42,380
TradjentaLinagliptin26$36,946
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog60$33,939
JanuviaSitagliptin Phosphate20$29,263
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog61$25,430
Novolog FlexpenInsulin Aspart79$24,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$169$545,942471 claims
Sanofi-aventis U.S. LLCLantus$112$1,49217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in River Forest

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →